DRUGS & SUPPLEMENTS

Sal Lite

Name: Sal Lite drug & pharmaceuticals. Sal Lite available forms, doses, prices
Creator: sdrugs.com
Published: 2021-11-11T10:10:10+00:00

When are you taking this medicine?

Sal Lite uses

Indications and usage
Contraindications
Warnings
Precautions
Adverse reactions
Overdosage
Dosage and administration
Instructions for use
How supplied
Im-0304
Im-0305
Sal Lite reviews

INDICATIONS AND USAGE

These solutions are indicated in patients requiring parenteral administration of Sal Lite and the replacement of extracellular losses of fluids and electrolytes with minimal carbohydrate calories.

CONTRAINDICATIONS

Solutions containing Sal Lite are contraindicated in diseases where high potassium levels may be encountered.

Solutions containing lactate are NOT FOR USE IN THE TREATMENT OF LACTIC ACIDOSIS.

WARNINGS

Solutions containing calcium ions should not be administered simultaneously through the same administration set as blood because of the likelihood of coagulation.

Solutions which contain potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present.

To avoid potassium intoxication, do not infuse these solutions rapidly. In patients with severe renal insufficiency or adrenal insufficiency, administration of Sal Lite may cause potassium intoxication.

Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.

In patients with diminished renal function, administration of solutions containing sodium or potassium ions may result in sodium or potassium retention.

Solutions containing lactate ions should be used with great care in patients with metabolic or respiratory alkalosis. The administration of lactate ions should be done with great care where there is an increased level or an impaired utilization of lactate ions, as in severe hepatic insufficiency.

The intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.

The risk of dilutional states is inversely proportional to the electrolyte concentration of administered parenteral solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.

PRECAUTIONS

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.

Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions, to patients receiving corticosteroids or corticotropin.

Potassium replacement therapy should be guided primarily by serial electrocardiograms. Plasma potassium levels are not necessarily indicative of tissue potassium levels.

High plasma concentrations of potassium may cause death through cardiac depression, arrhythmias or arrest.

Potassium-containing solutions should be used with caution in the presence of cardiac disease, particularly in digitalized patients or in the presence of renal disease.

Solutions containing lactate ions should be used with caution as excess administration may result in metabolic alkalosis.

Care should be exercised to insure that the needle (or catheter) is well within the lumen of the vein and that extravasation does not occur.

Do not administer unless solution is clear and container is undamaged. Discard unused portion.

Pregnancy Category C. Animal reproduction studies have not been conducted with dextrose, Sal Lite or Lactated Ringer’s Injection. It is also not known whether dextrose, Sal Lite or Lactated Ringer’s Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dextrose, Sal Lite or Lactated Ringer’s Injection should be given to a pregnant woman only if clearly needed.

Pediatric Use:

The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. In neonates or very small infants the volume of fluid may affect fluid and electrolyte balance.

Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants.

In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.

ADVERSE REACTIONS

Reactions which may occur because of the solutions or technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Nausea, vomiting, abdominal pain and diarrhea have been reported with potassium therapy. The signs and symptoms of potassium intoxication include paresthesias of the extremities, flaccid paralysis, listlessness, mental confusion, weakness and heaviness of the legs, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities such as disappearance of P waves, spreading and slurring of the QRS complex with development of a biphasic curve and cardiac arrest.

Potassium-containing solutions are intrinsically irritating to tissues. Therefore, extreme care should be taken to avoid perivascular infiltration. Local tissue necrosis and subsequent sloughing may result if extravasation occurs. Chemical phlebitis and venospasm have also been reported.

Should perivascular infiltration occur, I.V. administration at that site should be discontinued at once. Local infiltration of the affected area with procaine hydrochloride, 1%, to which hyaluronidase may be added, will often reduce venospasm and dilute the potassium remaining in the tissues locally. Local application of heat may also be helpful.

OVERDOSAGE

In the event of potassium overdosage, discontinue the infusion immediately and institute intensive corrective therapy to reduce serum potassium levels.

DOSAGE AND ADMINISTRATION

These solutions should be administered only by intravenous infusion and as directed by the physician. The dose and rate of injection are dependent upon the age, weight and clinical condition of the patient. If the serum potassium level is greater than 2.5 mEq/liter, potassium should be given at a rate not to exceed 10 mEq/hour in a concentration less than 30 mEq/liter. Somewhat faster rates and greater concentrations (usually up to 40 mEq/liter) of potassium may be indicated in patients with more severe potassium deficiency. The total 24-hour dose should not generally exceed 200 mEq of potassium.

As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.

Drug Interactions

Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.

The presence of calcium limits their compatibility with certain drugs that form precipitates of calcium salts, and also prohibits their simultaneous infusion through the same administration set as blood because of the likelihood of coagulation.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

INSTRUCTIONS FOR USE

To Open

Tear outer wrap at notch and remove solution container. If supplemental medication is desired, follow directions below beforepreparing for administration. Some opacity of the plastic due to moistureabsorption during the sterilization process may be observed. Thisis normal and does not affect the solution quality or safety. Theopacity will diminish gradually.

To Add Medication

Prepare additive port.
Using aseptic technique and an additive deliveryneedle of appropriate length, puncture resealable additive port attarget area, inner diaphragm and inject. Withdraw needle after injectingmedication.
The additive port may be protected by covering withan additive cap.
Mix container contents thoroughly.

Preparation for Administration

(Use aseptic technique)

Close flow control clamp of administration set.
Remove cover from outlet port at bottom of container.
Insert piercing pin of administration set into portwith a twisting motion until the set is firmly seated. NOTE: See full directions on administrationset carton.
Suspend container from hanger.
Squeeze and release drip chamber to establish properfluid level in chamber.
Open flow control clamp and clear air from set. Closeclamp.
Attach set to venipuncture device. If device is notindwelling, prime and make venipuncture.
Regulate rate of administration with flow controlclamp.

WARNING: Do not use flexiblecontainer in series connections.

HOW SUPPLIED

Intravenous solutions with Sal Lite (I.V. solution with KCl) are supplied in single-dose flexible plastic containers. See Table:

Sal Lite

in Lactated Ringer’s

and 5% Dextrose

Injection, USP

List No.

mEq

Potassium

Added

Size

(mL)

COMPOSITION (g/L)

Calculated

Osmolarity

(mOsmol/L)

Dextrose,

Hydrous

Potassium

Chloride

Sodium

Chloride

Sodium

Lactate,

Anhydrous

Calcium

Chloride

Dihydrate

7111

7113

20 mEq

40 mEq

1000

1.79

3.28

3.1

0.2

563

604

Sal Lite

in Lactated Ringer’s

and 5% Dextrose

Injection, USP (Continued)

Approx. Ionic Concentrations (mEq/L)

Approx.

kcal/L

Calcium

(Ca++)

Sodium

(Na⁺)

Potassium

(K⁺)

Chloride

(Cl¯)

Lactate

4.9

(3.5 to 6.5)

4.9

(3.5 to 6.5)

2.7

130

129

149

179

May contain HCl for pH adjustment.

Store at 20 to 25°C (68 to 77°F). Protect from freezing.

Revised: October, 2006

EN-1319 Printed in USA

Hospira, Inc., Lake Forest, IL 60045 USA

IM-0304

IM-0305

Sal Lite pharmaceutical active ingredients containing related brand and generic drugs:

Sal Lite available forms, composition, doses:

Powder; Oral; Potassium Chloride 49.85%; Sodium Chloride 49.85%

Sal Lite destination | category:

Human:
Replacement preparations

Sal Lite Anatomical Therapeutic Chemical codes:

B05BB01 - Electrolytes

Sal Lite pharmaceutical companies:

Rider Laboratorios

References

Dailymed."NASAL SPA NATURAL SEA SALT (SODIUM CHLORIDE) SPRAY [NACUR HEALTHCARE LTD]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
Dailymed."POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE [BRYANT RANCH PREPACK]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
Dailymed."AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Sal Lite?

Depending on the reaction of the Sal Lite after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Sal Lite not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Sal Lite addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

Review

sdrugs.com conducted a study on Sal Lite, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Sal Lite consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.